Hikal Ltd.    
22 Jun 2020
167.90
-2.50%
BP Wealth
revenues. EBIT margin of Crop protection segment improved by 302bps (YoY) with ~46% contribution Target Price (INR) to overall EBIT. Pharmaceutical segment EBIT margin contracted by 45bps with ~54% contribution to overall EBIT. PAT came below our estimate at INR245mn (est INR329mn) dragged by operationally weak performance and higher tax expenses (35.1% vs 30.8%). On RM Sourcing from China: Hikal...
default
Hikal Ltd. is trading below it's 30 day SMA of 176.6
Hikal Ltd.    
20 Jun 2020
167.90
-2.50%
buy
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in the year 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at 13.1% CAGR in FY20-22E to | 1135.3 crore on the back of new offerings and repeat business from CDMO customers. Crop protection growth to piggyback on client relationship...
Hikal Ltd. has an average target of 152.50 from 2 brokers.
Hikal Ltd.    
07 Feb 2020
167.90
-2.50%
buy
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...
Hikal Ltd. has gained 44.87% in the last 6 Months
Hikal Ltd.    
29 Oct 2019
167.90
-2.50%
buy
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...
Hikal Ltd. is trading above it's 200 day SMA of 129.9
Hikal Ltd.    
29 Oct 2019
167.90
-2.50%
BP Wealth
custom duty) of INR154mn. The company posted revenues of INR 3,211mn with 18.7% YoY decline which was below our estimate of INR,4,845mn. Multiple factors affected revenue growth during the quarter such as 1) Crop protection business was affected by heavy flooding at Mahad facility in the month of august which led to temporary production shut down.2) Pharmaceutical business faced issue at taloja facility where MIDC had cut 50% of the water supply to all industries in that region during Q2 and destocking of some of the products by innovator clients led to postponement in product...
Hikal Ltd. is trading above it's 200 day SMA of 129.9
Hikal Ltd.    
02 Aug 2019
167.90
-2.50%
ICICI Securities Limited
Q1 revenues grew 23.8% YoY to | 403.2 crore (I-direct estimate: | 368.4 crore) on account of 15.2% YoY growth in pharma segment to | 203.9 crore (I-direct estimate: | 212.4 crore) and 34.1% YoY growth in crop protection segment to | 199.3 crore (I-direct estimate: | 156.1 crore). EBITDA margins contracted 163 bps YoY to 17.0%, (I-direct estimate: 18.5%), fall in gross margins (43.4% vs. 49.4% in Q1FY19) was partly offset by decline in other expenditure. EBITDA grew 13% YoY to | 68.5 crore (I-direct estimate: | 68.1 crore. Net profit grew 58.4% YoY to | 25.2 crore (I-direct estimate of | 18.5...
Hikal Ltd. has gained 44.87% in the last 6 Months
Hikal Ltd.    
13 May 2019
167.90
-2.50%
BP Wealth
in gross margin due to change in product mix, EBITDA margin manage to remain at 18.4% level, was 121bps lower than our estimate. Adj. PAT came above our estimate at INR333mn (est INR298mn) Sector Outlook supported by lower tax expense (30.8% vs 35.3%) and decline in interest cost....
Hikal Ltd. has gained 44.87% in the last 6 Months
Hikal Ltd.    
10 May 2019
167.90
-2.50%
ICICI Securities Limited
Q4 revenues grew 17.2% YoY to | 457.5 crore (I-direct estimate: | 450.3 crore) on account of 20.7% YoY growth in the pharma segment to | 259.2 crore (I-direct estimate: | 268.4 crore) and 12.8% YoY growth in the crop protection segment to | 198.4 crore (I-direct estimate: | 175.8 crore). EBITDA margins remained at ~18.4%, (I-direct estimate: 19.2%). The fall in gross margins (75.8% vs. 79.3% in Q4FY18) was offset by a decline in employee cost and other expenditure. EBITDA grew 17.5% YoY to | 84 crore vis--vis I-direct estimate of | 86.6 crore. Net profit grew 31.6% YoY to | 33.3...
default
Hikal Ltd.'s price crossed below SMA50 today
Hikal Ltd.    
16 Apr 2019
167.90
-2.50%
Keynotes Financial Opiniery
One of very few global and only Indian company to provide Active Ingredients for both Pharmaceuticals Agrochemical Hybrid Model....
Hikal Ltd.'s price crossed below SMA50 today
Hikal Ltd.    
19 Mar 2019
167.90
-2.50%
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in the year 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...
default
Hikal Ltd. has an average target of 152.50 from 2 brokers.